Max Healthcare Institute Limited (MAXHEALTH:NSE) Stock Forecast
Alert
Its only available to paid users.
INR 1,245.00
(+14.76%)
Based on the Max Healthcare Institute Limited stock forecast from 3 analysts, the average analyst target price for Max Healthcare Institute Limited is INR 1,245.00 over the next 12 months. Max Healthcare Institute Limited’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Max Healthcare Institute Limited is Slightly Bearish, which is based on 5 positive signals and 8 negative signals. At the last closing, Max Healthcare Institute Limited’s stock price was INR 1,084.90. Max Healthcare Institute Limited’s stock price has changed by -9.47% over the past week, -8.06% over the past month and +47.12% over the last year.
No recent analyst target price found for Max Healthcare Institute Limited
No recent average analyst rating found for Max Healthcare Institute Limited
Company Overview Max Healthcare Institute Limited
Max Healthcare Institute Limited provides medical and healthcare services in India. It offers services in various specialties, including advanced cardiac care, orthopaedics, oncology, renal sciences, neurosciences, minimal access metabolic and bariatric surgery, obstetrics, gynaecology, paediatrics, nephrology, and general surgery, as well as liver, heart, kidney, lung and bone marrow transplants. The company also provides Max@Home, a platform that offers health and wellness services at home; and MaxLab, which provides diagnostic services to patients outside its network of hospitals through various channels comprising third-party hospital laboratory management. It operates through a network of healthcare facilities, including hospitals and medical centres. The company was incorporated in 2001 and is based in Gurugram, India. Read Less
Max Healthcare Institute Limited provides medical and healthcare services in India. It offers services in various specialties, including advanced cardiac care, orthopaedics, oncology, renal sciences, neurosciences, minimal access metabolic and bariatric surgery, obstetrics, gynae...Read More
Frequently Asked Questions About Max Healthcare Institute Limited (MAXHEALTH:NSE) Stock
Based on ratings from 3 analysts Max Healthcare Institute Limited's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 4 buy, sell and hold ratings.
MAXHEALTH:NSE stock's dividend yield is 0.13%.
Our analysis grades MAXHEALTH:NSE stock's dividend yield at F. This means that MAXHEALTH:NSE stock's dividend yield is above 20% of the stocks in the Medical Care Facilities sector in the NSE exchange.
Based on this MAXHEALTH:NSE may be a poor dividend stock for its sector.
Based on targets from 3 analysts, the average taret price for MAXHEALTH:NSE is INR 1,245.00 over the next 12 months. The maximum analyst target price is INR 1315 while the minimum anlayst target price is INR 1185.
MAXHEALTH:NSE stock's Price/Earning ratio is 106.82.
Our analysis grades MAXHEALTH:NSE stock's Price / Earning ratio at F. This means that MAXHEALTH:NSE stock's Price/Earning ratio is above 79% of the stocks in the Medical Care Facilities sector in the NSE exchange.
Based on this MAXHEALTH:NSE may be a overvalued for its sector.
The last closing price of MAXHEALTH:NSE's stock was INR 1,084.90.
The most recent market capitalization for MAXHEALTH:NSE is INR 1,124.66B.
Based on targets from 3 analysts, the average taret price for MAXHEALTH:NSE is projected at INR 1,245.00 over the next 12 months.
This means that MAXHEALTH:NSE's stock price may go up by +14.76% over the next 12 months.
We can't find any ETFs which contains Max Healthcare Institute Limited's stock.
As per our most recent records Max Healthcare Institute Limited has 19,500 Employees.
Max Healthcare Institute Limited's registered address is Capital Cyberscape, Gurugram, India, 122 102.
You can get more information about it from Max Healthcare Institute Limited's website at https://www.maxhealthcare.in.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
What not to like
Poor return on assets
The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Poor return on equity
The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Max Healthcare Institute Limited (MAXHEALTH:NSE) Stock
Based on ratings from 3 analysts Max Healthcare Institute Limited's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 4 buy, sell and hold ratings.
MAXHEALTH:NSE stock's dividend yield is 0.13%.
Our analysis grades MAXHEALTH:NSE stock's dividend yield at F. This means that MAXHEALTH:NSE stock's dividend yield is above 20% of the stocks in the Medical Care Facilities sector in the NSE exchange.
Based on this MAXHEALTH:NSE may be a poor dividend stock for its sector.
Based on targets from 3 analysts, the average taret price for MAXHEALTH:NSE is INR 1,245.00 over the next 12 months. The maximum analyst target price is INR 1315 while the minimum anlayst target price is INR 1185.
MAXHEALTH:NSE stock's Price/Earning ratio is 106.82.
Our analysis grades MAXHEALTH:NSE stock's Price / Earning ratio at F. This means that MAXHEALTH:NSE stock's Price/Earning ratio is above 79% of the stocks in the Medical Care Facilities sector in the NSE exchange.
Based on this MAXHEALTH:NSE may be a overvalued for its sector.
The last closing price of MAXHEALTH:NSE's stock was INR 1,084.90.
The most recent market capitalization for MAXHEALTH:NSE is INR 1,124.66B.
Based on targets from 3 analysts, the average taret price for MAXHEALTH:NSE is projected at INR 1,245.00 over the next 12 months.
This means that MAXHEALTH:NSE's stock price may go up by +14.76% over the next 12 months.
We can't find any ETFs which contains Max Healthcare Institute Limited's stock.
As per our most recent records Max Healthcare Institute Limited has 19,500 Employees.
Max Healthcare Institute Limited's registered address is Capital Cyberscape, Gurugram, India, 122 102.
You can get more information about it from Max Healthcare Institute Limited's website at https://www.maxhealthcare.in.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for MAXHEALTH:NSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
